C4x Discovery Share Discussion Threads

[alloa2003] 06/5/2021 09:58

This latest fall, and the appointment of the new bloke recently, has the smell of another fund raising - surely not?

[bloomberg2] 01/5/2021 12:15

Come on Toffeeman ! Give old Dixi some slack

[toffeeman] 01/5/2021 09:33

Just a shame he can't nail C4XD

[bloomberg2] 01/5/2021 07:39

Bingham & Dixi nailed it !!!

[ayl30] 01/5/2021 07:38

Dixhttps://www.thetimes.co.uk/article/clive-dix-its-beyond-belief-that-we-got-the-covid-vaccines-ready-in-less-than-a-year-0hgdrb3gz?shareToken=20d5b693830b04de09e16c2b955b27b3

[charlie9038] 29/4/2021 17:52

I also think it is strange there was no movement on today TU

[astorcourt] 29/4/2021 14:04

I find it strange that there is little movement in share price on release of interims.

[alloa2003] 29/4/2021 11:26

I think that takes in the INDV deal and the new one. The next INDV payment cant be too far away.

[t0pgrader] 29/4/2021 10:23

The statement "a roadmap of potential cash milestones over the next 12-24 months" is ambiguous. Does it mean anytime from month 1 onwards or from month 13 to 24?

In this regard I am expecting a milestone payment from Indivior on the publication of their P1 single dose results and possibly a second associated with the multiple ascending dose trial. Any thoughts?

[charlie9038] 29/4/2021 09:08

MC 94m at 41p seems a bargain with the TU today. Anyone good on here with figures?

[bamboozler] 29/4/2021 08:22

Good progress across the portfolio and so reassuring to see such a solid cash position.

[charlie9038] 29/4/2021 07:41

Looks good to me:

a €414 million agreement

§ Exclusive worldwide licensing agreement with Sanofi for C4XD's IL-17A oral inhibitor programme worth up to €414 million including:

§ €7 million upfront

§ €407 million in potential development, regulatory and commercialisation milestones, of which €11 million is in pre-clinical milestones

§ Potential for single-digit royalties

[alloa2003] 28/4/2021 16:44

I wonder what the figures will hold tomorrow morning?

[alanrussell] 21/4/2021 18:11

That's very interesting Bamboozler, thanks for posting.

[bamboozler] 21/4/2021 17:24

https://www.proactiveinvestors.co.uk/companies/news/947260/c4x-discovery-happy-in-the-pre-clinical-world-as-partner-list-grows-947260.html

[alloa2003] 20/4/2021 17:57

Yip, agree. The Americans love a company with huge hope value - just look at Tesla!

[alloa2003] 20/4/2021 15:14

New board appointment which to be fair is just what the doctor ordered:-

"20 April 2021 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces the appointment of Simon Harford as Non-Executive Director with immediate effect.

Simon joins C4XD with more than 30 years of significant financial and investor relations expertise in global pharmaceutical companies. Simon is currently CFO at Albireo Pharma Inc., a NASDAQ-listed biotech company where he has raised more than $200 million in equity financing and was previously CFO of Parexel International Inc., a global clinical research organisation, which was acquired by private equity in 2017. Prior to this, Simon held various financial leadership roles at GSK, including SVP Finance, Global Pharmaceuticals. During his tenure, he was responsible for finance in all pharmaceutical markets globally and was a member of the Global Pharmaceutical Operations Committee. Simon also held key financial management roles at Eli Lilly and Company over two decades including Vice President and Controller, CFO and Executive Director Finance for Europe, Middle East and Africa (EMEA) and led the global investor relations function as Executive Director of Investor Relations. He also received the Lilly, Chairman's Ovation Award 2004 for outstanding achievement to Lilly.

Eva-Lotta Allan, Chairman of C4X Discovery, said: "Simon brings a wealth of global pharmaceutical expertise across key financial markets, including the US where he is based. His deep understanding of global pharmaceutical financial strategy will be invaluable as we continue to grow C4XD and expedite major out-licensing deals such as our recent deals with Sanofi and Indivior. We welcome Simon to the Board and look forward to working closely with him."

Simon Harford, incoming Non-Executive Director, added: "I am delighted to be joining the C4XD Board at this stage of the Company's development. C4XD has made great progress in the execution of its strategy, which the recent deal with Sanofi further validates. The Company's technologies are able to deliver high quality and differentiated drug candidates for development by pharma and biotech companies and I look forward to working with the Board to continue growing the Company and delivering shareholder value."

[t0pgrader] 20/4/2021 14:38

There was no milestone payment received from Indivior at the outset of the P1 clinical trial so there could be one upon its conclusion. FWIW C4XD interim results were 29 / 4 last year.

[bamboozler] 20/4/2021 14:36

Oh...I will do!!!

[t0pgrader] 20/4/2021 14:32

@bamboozier - might perhaps relate to the impeding completion of the Indivior P1 trial for INDV2000?

[charlie9038] 20/4/2021 14:30

Don't worry Hold on & enjoy the ride ;)

[bamboozler] 20/4/2021 14:17

Anyone got any idea what caused today's sudden turnaround?It looks quite odd.

[1aconic] 18/4/2021 07:58

Yes, I've seen that about the delivery system too. But my understanding is that it's in addition to the idea that their discovery process is also intended to increase success rates. So on the two licensed deals there are double factors increasing the standard probabilities of making it through trials. They're obviously still a long shot but at least this week there are now two long shots rather than one! I'm right on board with the view that the main takeaway from the Sanofi deal isn't really the potential revenue but that it's further proof of concept and that the revenue boost short term allows other projects to progress with less chance of another capital raise needed.